<a href="https://www.fiercebiotech.com/biotech/asco-long-term-early-data-backs-tremendous-potential-takedas-innovent-oncology-collab" hreflang="en">ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data</a>
At the ASCO 2026 conference, Takeda highlighted the promising survival data for Innovent Biologics' bispecific therapy IBI363, designed to treat advanced immunotherapy-resistant non-small cell lung cancer, showcasing significant progression-free and overall survival rates. The collaboration between Takeda and Innovent, which includes a multi-billion-dollar partnership, aims to leverage the unique capabilities of IBI363 to enhance cancer treatment outcomes.
Takeda's collaboration with Innovent Biologics, particularly around the development of the PD-1/IL-2 bispecific candidate IBI363, showcases a promising advancement in the treatment of advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). The therapy's innovative mechanism, which combines PD-1 blockade with IL-2 activation, has shown robust survival benefits in early clinical trials, and its FDA fast-track designation positions it as a significant player in the oncology space. For someone tracking investment signals, Takeda's substantial financial commitment to this collaboration indicates confidence in IBI363's potential and Innovent's innovative pipeline, making it a noteworthy area for further investment consideration.